Novel Immunotherapy Boosts Melanoma Outcomes

(MedPage Today) -- A dual immunotherapy regimen targeting the novel lymphocyte-activation gene 3 (LAG-3) immune checkpoint led to a significant progression-free survival (PFS) benefit in patients with advanced melanoma, according to a phase III...